The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
Ask the Experts About

Choosing Your MedsChoosing Your Meds
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  • Email Email
  • Glossary Glossary

PI Pill Burden

Mar 7, 2004

Dear Dr Young

My question is about PI based therapy for those resistant to NNRTIs. Is there any future hope that the pill burden may be reduced ? Will Kaletra for example always require at least 6 pulss/day or will there be new PIs coming out that will help reduce pill burden?


Response from Dr. Young

Thanks for your question.

News Flash: Pill burden for protease inhibitors has been reduced.

Kaletra represented the first of a newer set of protease inhibitors-- it reduced pill counts (as you point out) to three pills twice daily. There's not need to hope for lower pill burden, low pill burden PIs are already here.

Last year, two new PIs, atazanavir (Reyataz) and fosamprenavir (Lexiva) were approved for use in the US. Used with ritonavir boosting, the total pill counts (including the ritonavir) are 3 and 4. Unboosted, the pill burdens are 2 (for taz) and 4 (for fosamprenavir). Together, the pill burden for these new PIs are essentially the same as the initial pill burden for the highly successful NNRTI, efavirenz (Sustiva).

Thanks for reading. BY

when do I start
Zoloft and anti virals

  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS



This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint